EYENOVIA
Eyenovia is a biopharmaceutical company that provides portfolio of next generation topical eye treatments. It is a clinical stage, ophthalmic biopharmaceutical company that transforms the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics. Eyenovia was founded in 2014.
EYENOVIA
Industry:
Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.eyenovia.com
Total Employee:
11+
Status:
Active
Contact:
(917) 289-1117
Email Addresses:
[email protected]
Total Funding:
53.14 M USD
Technology used in webpage:
Amazon Amazon Route 53 Amazon Ohio Region
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Eyenovia
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Eyenovia
Key Employee Changes
Official Site Inspections
http://www.eyenovia.com Semrush global rank: 5.06 M Semrush visits lastest month: 1.63 K
- Host name: 45.184.227.35.bc.googleusercontent.com
- IP address: 35.227.184.45
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Eyenovia"
Eyenovia - Crunchbase Company Profile & Funding
Eyenovia’s breakthrough. piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of …See details»
Eyenovia, Inc. - LinkedIn
Eyenovia, Inc. (NASDAQ: EYEN), is an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for …See details»
Investor Relations | Eyenovia Inc.
Sep 27, 2024 Eyenovia is a public eye care company with topical ophthalmic therapies that are easier to use and easier to live with. The Optejet® is the only FDA-approved ophthalmic spray …See details»
Eyenovia Company Profile - Office Locations, Competitors ... - Craft
Aug 23, 2024 Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. The …See details»
Eyenovia Provides Update on Phase 3 CHAPERONE Study
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that a review of the CHAPERONE data by …See details»
Company - Eyenovia
Eyenovia, Inc. (NASDAQ: EYEN) created the Optejet® to be a more effective, safer, and smarter way to administer medication to the eyes over traditional eyedroppers. The Optejet was …See details»
Eyenovia Provides Update on Restructuring Efforts - Yahoo Finance
Nov 22, 2024 Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic technology company developing and commercializing products leveraging its proprietary Optejet topical ophthalmic …See details»
Eyenovia Announces Updated Strategy and Corporate Priorities to …
Apr 8, 2024 Eyenovia, Inc. Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and …See details»
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct …
6 days ago NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and …See details»
Eyenovia Announces Updated Strategy and Corporate Priorities to …
Apr 8, 2024 Eyenovia Investor Contact: Eric Ribner LifeSci Advisors, LLC [email protected] (646) 751-4363. Eyenovia Media Contact: Eyenovia, Inc. Norbert …See details»
Eyenovia’s Direct Offering to Support Strategic Initiatives
5 days ago Eyenovia, Inc. has announced a registered direct offering worth approximately $1.3 million, involving the sale of over 12 million shares and warrants. The company plans to use …See details»
Management - Eyenovia
Eyenovia’s management team is comprised of distinguished and proven members from a multitude of backgrounds. Michael Rowe. Chief Executive Officer and President. Andrew …See details»
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial …
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on …See details»
Eyenovia Announces Changes to the Board of Directors
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print …See details»
Eyenovia Restructures Finances and Leadership Team - Nasdaq
6 days ago An update from Eyenovia ( (EYEN)) is now available. Eyenovia, Inc. has restructured its financial agreements by amending a Loan and Security Agreement with Avenue Capital …See details»
After Formosa snags FDA nod for reformulation of old steroid, …
Mar 5, 2024 As for the newly approved steroid nanosuspension, Eyenovia picked up the U.S. commercial rights to Formosa’s product last August. The eyecare specialist paid $2 million …See details»
EYENOVIA ANNOUNCES APPOINTMENT OF OPHTHALMIC …
Jul 27, 2022 Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization …See details»
Board of Directors - Eyenovia
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you …See details»
News - Eyenovia
NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use …See details»